Nektar Therapeutics price to sales ratio NKTR

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026: 23.3×
10-year median: 14.1×
Against its 10-year history: 65th; percentile: 0 is its lowest day, 100 its highest
10-year range: 1.0× to 56.7×
Peer median: 1.8×

Nektar Therapeutics' price to sales ratio is 23.3× as of Oct 23, 2026.

That is above its ten-year median of 14.1×, higher than on 65% of days in the last ten years.

Over that time it ranged from 1.0× in Nov 2023 to 56.7× in Mar 2018.

The median for 10 large drugmakers of a similar size is 1.8×.

Price to sales ratio over time

median 14.1×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	23.3×	12.0×	49.7×
2025	14.5×	1.0×	21.2×
2024	1.9×	1.1×	3.6×
2023	1.2×	1.0×	6.1×
2022	4.5×	4.3×	23.3×
2021	24.8×	18.2×	32.3×
2020	18.7×	17.4×	39.3×
2019	31.5×	4.6×	31.5×
2018	4.7×	4.2×	56.7×
2017	37.7×	11.0×	37.7×
2016	11.2×	6.7×	13.7×
2015	10.7×	4.8×	10.8×
2014	9.2×	8.1×	12.9×
2013	9.5×	8.8×	17.3×
2012	10.8×	9.1×	14.6×

Against its peers

Companies in Drug Manufacturers - General nearest Nektar Therapeutics' size, closest first, today.

Company	Price to sales ratio
NKTRNektar Therapeutics	23.3×
OMEROmeros	n/m
PCRXPacira BioSciences	1.9×
ANABAnaptysbio	n/m
AMPHAmphastar Pharmaceuticals	1.5×
PAHCPhibro Animal Health	1.0×
ANIPANI Pharmaceuticals	1.7×
ABUSArbutus Biopharma	4.6×
HRMYHarmony Biosciences	2.2×
COLLCollegium Pharmaceutical	0.9×
PBHPrestige Consumer Healthcare	2.0×
Peer median	1.8×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Nektar Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.